

NHS Standard Contract 2023/24

Particulars (Shorter Form)

PROVIDER –

SERVICE TITLE – Leeds Community Pharmacy - Signposting of Patients with Lung Cancer Symptoms to a Self-Referral Chest X-Ray Service (Pilot)

2024_25 Head Contract Reference: project_958 - 2023/24 Community Pharmacy Lung X-Ray Self-Referral Pilot/CPWY

Version 1, March 2023

Prepared by: NHS Standard Contract Team, NHS England
england.contractshelp@nhs.net
(please do not send contracts to this email address)

Contract Reference	project_958 - 2023/24 Community Pharmacy Lung X-Ray Self-Referral Pilot/CPWY
DATE OF CONTRACT	Date last party signs
SERVICE COMMENCEMENT DATE	1st February 2024
CONTRACT TERM	6 months commencing 1st February 2024 (or as extended in accordance with Schedule 1C)
COMMISSIONERS	West Yorkshire ICB (ODS QWO)
CO-ORDINATING Commissioner <i>See GC10</i>	West Yorkshire ICB (ODS QWO)
PROVIDER	Provider Name: ODS: Principal and/or registered office address: Company number:

CONTENTS

PARTICULARS

SCHEDULES

SCHEDULE 1 – SERVICE COMMENCEMENT AND CONTRACT TERM (Schedule 1B Intentionally Omitted)

- A. Conditions Precedent
- C. Extension of Contract Term

SCHEDULE 2 – THE SERVICES (Schedule 2C, 2E, 2F, 2H, 2I Intentionally Omitted)

- A. Service Specifications
- Ai. Service Specifications – Enhanced Health in Care Homes
- B. Indicative Activity Plan
- D. Essential Services (NHS Trusts only)
- G. Other Local Agreements, Policies and Procedures
- J. Transfer of and Discharge from Care Protocols
- K. Safeguarding Policies and Mental Capacity Act Policies

SCHEDULE 3 – PAYMENT (Schedule 3A Intentionally Omitted)

- B. Locally Agreed Adjustments to NHS Payment Scheme Unit Prices
- C. Local Prices
- D. Expected Annual Contract Values

SCHEDULE 4 – LOCAL QUALITY REQUIREMENTS

SCHEDULE 5 – INTENTIONALLY OMITTED

SCHEDULE 6 – CONTRACT MANAGEMENT, REPORTING AND INFORMATION REQUIREMENTS

(Schedules 6B, 6C, 6D Intentionally Omitted)

- A. Reporting Requirements
- E. Provider Data Processing Agreement

SCHEDULE 7 – PENSIONS

SCHEDULE 8 – TUPE

SERVICE CONDITIONS

(Service Conditions 7, 9, 14, 19-20, 22, 26-27, 31 intentionally omitted)

- SC1 Compliance with the Law and the NHS Constitution
- SC2 Regulatory Requirements
- SC3 Service Standards
- SC4 Co-operation
- SC5 Commissioner Requested Services/Essential Services
- SC6 Choice and Referrals
- SC8 Making Every Contact Count and Self Care
- SC10 Personalised Care
- SC11 Transfer of and Discharge from Care
- SC12 Communicating With and Involving Service Users, Public and Staff
- SC13 Equity of Access, Equality and Non-Discrimination
- SC15 Urgent Access to Mental Health Care
- SC16 Complaints
- SC17 Services Environment and Equipment
- SC18 Green NHS
- SC21 Infection Prevention and Control
- SC23 Service User Health Records
- SC24 NHS Counter-Fraud Requirements
- SC25 Other Local Agreements, Policies and Procedures
- SC28 Information Requirements
- SC29 Managing Activity and Referrals
- SC30 Emergency Preparedness, Resilience and Response
- SC32 Safeguarding Children and Adults
- SC33 Patient Safety
- SC34 End of Life Care
- SC35 Duty of Candour
- SC36 Payment Terms
- SC37 Local Quality Requirements

ANNEX A National Quality Requirements

GENERAL CONDITIONS

(General Conditions 6-7, 34-35 intentionally omitted)

- GC1 Definitions and Interpretation
- GC2 Effective Date and Duration
- GC3 Service Commencement
- GC4 Transition Period
- GC5 Staff
- GC8 Review
- GC9 Contract Management
- GC10 Co-ordinating Commissioner and Representatives
- GC11 Liability and Indemnity
- GC12 Assignment and Sub-Contracting
- GC13 Variations
- GC14 Dispute Resolution
- GC15 Governance, Transaction Records and Audit
- GC16 Suspension
- GC17 Termination
- GC18 Consequence of Expiry or Termination
- GC19 Provisions Surviving Termination
- GC20 Confidential Information of the Parties
- GC21 Patient Confidentiality, Data Protection, Freedom of Information and Transparency

GC22 Intellectual Property
GC23 NHS Identity, Marketing and Promotion
GC24 Change in Control
GC25 Warranties
GC26 Prohibited Acts
GC27 Conflicts of Interest and Transparency on Gifts and Hospitality
GC28 Force Majeure
GC29 Third Party Rights
GC30 Entire Contract
GC31 Severability
GC32 Waiver
GC33 Remedies
GC36 Notices
GC37 Costs and Expenses
GC38 Counterparts
GC39 Governing Law and Jurisdiction

Definitions and Interpretation

CONTRACT

Contract title: Leeds Community Pharmacy - signposting of patients with lung cancer symptoms to a self-referral chest x-ray service (pilot)

Contract ref: project_958 - 2023/24 Community Pharmacy Lung X-Ray Self-Referral **Pilot/CPWY**

This Contract records the agreement between the Commissioners and the Provider and comprises

1. these **Particulars**, as completed and agreed by the Parties and as varied from time to time in accordance with GC13 (*Variations*);
2. the **Service Conditions (Shorter Form)**, as published by NHS England from time to time at: <https://www.england.nhs.uk/nhs-standard-contract/>;
3. the **General Conditions (Shorter Form)**, as published by NHS England from time to time at: <https://www.england.nhs.uk/nhs-standard-contract/>.

Each Party acknowledges and agrees

- (i) that it accepts and will be bound by the Service Conditions and General Conditions as published by NHS England at the date of this Contract, and
- (ii) that it will accept and will be bound by the Service Conditions and General Conditions as from time to time updated, amended or replaced and published by, NHS England pursuant to its powers under regulation 17 of the National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, with effect from the date of such publication.

IN WITNESS OF WHICH the Parties have signed this Contract on the date(s) shown below

SIGNED by



Signature

**[INSERT AUTHORISED SIGNATORY'S NAME] for
and on behalf of
[INSERT COMMISSIONER NAME]**

**Associate Director of Partner Relationship
Management**

.....
Title

7/2/2024

.....
Date

SIGNED by

.....
Signature

**[INSERT AUTHORISED
SIGNATORY'S
NAME] for
and on behalf of
[INSERT Community Pharmacy
provider name]**

.....
Title

.....
Date

SERVICE COMMENCEMENT AND CONTRACT TERM	
Effective Date <i>See GC2.1</i>	[The date of this Contract]
Expected Service Commencement Date <i>See GC3.1</i>	1 st February 2024
Longstop Date <i>See GC4.1</i>	1 st March 2024
Contract Term	6 months commencing (or as extended in accordance with Schedule 1C)
Commissioner option to extend Contract Term <i>See Schedule 1C, which applies only if YES is indicated here</i>	YES
Notice Period (for termination under GC17.2)	1 month
SERVICES	
Service Categories	Indicate <u>all</u> categories of service which the Provider is commissioned to provide under this Contract. <i>Note that certain provisions of the Service Conditions and Annex A to the Service Conditions apply in respect of some service categories but not others.</i>
Continuing Healthcare Services (including continuing care for children) (CHC)	
Community Services (CS)	
Diagnostic, Screening and/or Pathology Services (D)	
End of Life Care Services (ELC)	
Mental Health and Learning Disability Services (MH)	
Patient Transport Services (non-emergency) (PT)	

GOVERNANCE AND REGULATORY

Provider's Nominated Individual	Name: Email: Tel:
Provider's Information Governance Lead	Name: Email: Tel:
Provider's Data Protection Officer (if required by Data Protection Legislation)	Name: Email: Tel:
Provider's Caldicott Guardian	Name: Email: Tel:
Provider's Senior Information Risk Owner	Name: Email: Tel:
Provider's Accountable Emergency Officer	Name: Email: Tel:
Provider's Safeguarding Lead (children) / named professional for safeguarding children	Name: Email: Tel:
Provider's Safeguarding Lead (adults) / named professional for safeguarding adults	Name: Email: Tel:
Provider's Child Sexual Abuse and Exploitation Lead	Name: Email: Tel:
Provider's Mental Capacity and Liberty Protection Safeguards Lead	Name: Email: Tel:
Provider's Freedom To Speak Up Guardian(s)	Name: Email: Tel:

CONTRACT MANAGEMENT

Addresses for service of Notices <i>See GC36</i>	Co-ordinating Commissioner: West Yorkshire ICB Rachel McCluskey Head of Contracting Address: White Rose House, West Parade, Wakefield, WF1 1LT Email: rachel.mccluskey1@nhs.net Provider: Address: Email:
Frequency of Review Meetings	Ad hoc
Commissioner Representative(s) <i>See GC10.2</i>	Tom Daniels Address: White Rose House, West Parade, Wakefield, WF1 1LT Email: Tom.daniels@nhs.net
Provider Representative <i>See GC10.2</i>	Name: Address: Email: Tel:

SCHEDULE 1 – SERVICE COMMENCEMENT AND CONTRACT TERM

A. Conditions Precedent

The Provider must provide the Co-ordinating Commissioner with the following documents and complete the following actions:

- | |
|---|
| 1. Evidence of appropriate Indemnity Arrangements |
|---|

C. Extension of Contract Term

To be included only in accordance with the Contract Technical Guidance. Either include the text below or delete it and state Not Applicable.

1. The Commissioners may opt to extend the Contract Term by up to 2 months.
2. If the Commissioners wish to exercise the option to extend the Contract Term, the Co-ordinating Commissioner must give written notice to that effect to the Provider no later than 1 month before the original Expiry Date.
3. The option to extend the Contract Term may be exercised:
 - 3.1 only once, and only on or before the date referred to in paragraph 2 above;
 - 3.2 only by all Commissioners; and
 - 3.3 only in respect of all Services.
4. If the Co-ordinating Commissioner gives notice to extend the Contract Term in accordance with paragraph 2 above, the Contract Term will be extended by the period specified in that notice and the Expiry Date will be deemed to be the date of expiry of that period.

SCHEDULE 2 – THE SERVICES

A. Service Specification

1. Service Description

This pilot project seeks to investigate the viability of signposting of patients with symptoms of possible lung cancers towards an established self-referral chest x-ray (SRCXR) service provided by Leeds Teaching Hospitals NHS Trust from community pharmacies across Leeds. A stage-shift in lung cancer was described following an increase in community chest x-ray (CXR) imaging prompted by a lung cancer awareness campaign in Leeds (1). Recent evidence suggests that increased use of primary-care CXR is associated with earlier lung cancer diagnosis and reduced all-cause mortality (2). NICE recommends a CXR for patients with unexplained, persistent respiratory symptoms but there is evidence to demonstrate that many patients experience barriers to accessing timely CXR in primary care (3,4). A study linking primary care and cancer registry data showed increased rates of prescriptions for antibiotics, steroids and inhaled bronchodilators up to 5 months before a lung cancer diagnosis (5). Changes in medication usage may provide an opportunity to signpost patients with respiratory symptoms towards the SRCXR service, thereby increasing the potential to diagnose patients at an earlier stage of disease.

This project builds on previous pilots which confirmed the viability of such initiatives but identified challenges in the ability of community pharmacy services to routinely make referrals into radiology services as a barrier to wider adoption (6,7,8). This project seeks to identify whether signposting patients with symptoms of potential lung cancer towards a pre-established SRCXR service would provide a viable alternative to address this issue and capitalise on the potential of community pharmacy to engage with patients with early symptoms. This project has been successfully awarded an innovation grant by the West Yorkshire & Harrogate Cancer Alliance to undertake a pilot to determine the potential impact and viability of implementing this development in practice.

Participation for this pilot will be restricted to community pharmacies operating within Leeds. The SRCXR service is currently only provided by the Leeds Teaching Hospitals NHS Trust.

Participating pharmacies will be provided with appropriate training to identify and signpost eligible patients to the SRCXR service based on a combination of clinical presentation and medication usage (as defined within the patient eligibility section). Eligible patients identified by participating community pharmacies will then receive a brief intervention from a pharmacist or pharmacy technician (as outlined in the training) signposting patients towards the SRCXR service and provide patients with a printed “SRCXR service signposting card” (supplied to participating community pharmacies by the West Yorkshire ICB cancer board pilot project team, (see appendices)) Participating community pharmacies will be required to provide a limited, non-patient identifiable dataset (as outlined in the records and documentation section) using a dedicated data collection form created on the PharmOutcomes system specifically for this pilot. Payment (as outlined payment section) will be provided to participating community pharmacies based on engagement in all aspects of this pilot project outlined within this service specification (staff training, patient identification, conducting the brief intervention/signposting and recording of data of the PharmOutcomes system).

This service is limited to community pharmacies operating in the Leeds area. The SRCXR service to which patients will be signposted is currently only provided locally by the Leeds Teaching Hospitals NHS Trust.

This pilot project has received a non-recurring grant from the West Yorkshire & Harrogate Cancer Alliance. As such this pilot will operate for a 6 month period (anticipated 01/02/2024 to 31/07/2024) or until 2,500 eligible patients have been signposted, whichever occurs first.

objectives

2.1 Aim

This project aims to assess the viability of signposting patients with possible lung cancer symptoms towards an established self-referral chest x-ray service from community pharmacies within the Leeds area.

2.2 Objectives

1. Identify the number of patients who present to community pharmacies who would benefit from a CXR to investigate lung cancer based on symptoms/medication usage.
2. Identify the frequency with which medications identified by Wickramasinghe et al⁵ are prescribed for/purchased by patients who would benefit from a CXR to investigate possible lung cancers
3. Identify the number of patients who present to SRCXR services who were signposted from a participating community pharmacy

3. Eligibility and Recruitment of Participating Community Pharmacies

3.1 Eligibility

This pilot project is limited to community pharmacies operating in the Leeds area. The SRCXR service is currently only provided by the Leeds Teaching Hospitals NHS Trust.

3.2 Recruitment

This pilot project is open to all community pharmacy providers across the Leeds region with the exception of distance selling pharmacies. A decision to exclude distance selling pharmacies has been made on the basis the self-referral chest x-ray service is restricted to patients within the Leeds area and is not a nationally commissioned programme.

The West Yorkshire ICB Cancer Board is working closely with Community Pharmacy West Yorkshire to coordinate this pilot project. As part of this working partnership, Community Pharmacy West Yorkshire will contact all community pharmacy providers (as outlined above) across the Leeds region with details of this pilot project and coordinate collection of completed service level agreements from participating community pharmacies.

4. Patient Eligibility

4.1 Patient Eligibility Inclusion Criteria

Patients must fulfil the following criteria to be eligible to be signposted to the SCRXR service:

- Patients must be at least 40 years old at the time they are identified/signposted from participating community pharmacies.

- Patients must not have received a chest x-ray within the previous 3 months (12 weeks) at the time that they are identified/signposted from participating community pharmacies.

Symptoms

Patient must also have at least one of the following symptoms lasting at least 3 weeks (21 days) at the time of presentation to a participating community pharmacy:

- Cough
- Difficulty in breathing
- Loss of appetite or weight
- Chest pain
- Fatigue or tiredness

Patients who do not fulfil the criteria outlined above are ineligible to participate within this pilot project. Patients who are ineligible who present with symptoms which require investigation should be signposted to their GP/walk in centre.

Please note that all patients who fulfil the criteria outlined above, irrespective of smoking status, are eligible to participate in this pilot project.

All patients who are signposted to the SRCXR service must attend the participating community pharmacy in person to enable the pharmacist or pharmacy technician to assess their eligibility (based on the criteria outlined above) as part of the brief intervention process.

4.2 Patients Eligibility Exclusion Criteria

Patients who do not fulfil the inclusion criteria outlined above will not be eligible for inclusion within the scope of this pilot project. Additionally, patients from the following will be excluded:

- Patients who present with severe symptoms (e.g. hemoptysis, acute dyspnea) which require immediate medical intervention should be signposted to their GP/walk in centre or A&E as clinically appropriate. It is the responsibility of the pharmacist to identify patients who require immediate medical intervention, as would be considered appropriate within routine clinical practice. Please note, this list of suggested severe symptoms is not exhaustive and it is the responsibility of the attending pharmacist to exercise appropriate clinical judgement.
- Patients who have received a chest x-ray within the previous 3 months (12 weeks).
- Patients who are signposted from community pharmacies which have not returned a completed service level agreement form will not be eligible to be remunerated as per the content outlined within this document.

5. Requirements for Service Provision – Premises, Training and Other Requirements

5.1 Requirements for participating community pharmacy operators/businesses

This pilot project is limited to community pharmacies operating within Leeds. The SRCXR service is currently only provided by the Leeds Teaching Hospitals NHS Trust.

Pharmacy contractors must agree with the terms outlined within this service level agreement and have returned a signed copy to the Community Pharmacy West Yorkshire.

Community pharmacies must be fully compliant with the essential services and clinical governance requirements of the Community Pharmacy Contractual Framework (CPCF).

Community pharmacies must be compliant with their obligations under schedule 4 of the NHS (pharmaceutical and local pharmaceutical services) Regulations (terms of service of NHS Pharmacists) in respect of the provision of essential services and acceptable systems of clinical governance.

Pharmacy contractors should ensure, as far as is practicable, that all pharmacists and/or pharmacy technicians employed to work within the participating pharmacy (including locum staff) have undertaken the appropriate training (as defined within the training section). Pharmacists who have not undertaken this training will be ineligible to conduct the brief intervention and signpost patients to the SRCXR service.

Pharmacy contractors must read through this service level agreement and agree to the requirements detailed within (including requirements to receive remuneration – as detailed in the payments section).

Pharmacy contractors assume responsibility for delivering this pilot project within the terms outlined within this service level agreement.

5.2 Requirements for pharmacists and pharmacy technicians employed within participating community pharmacies

Please note, locum staff as subject to the same requirements as substantive contracted staff for the purposes of this pilot project

Pharmacists and pharmacy technicians should ensure that they have completed the appropriate training (as defined within the training section).

Pharmacists and pharmacy technicians must read and understand this service level agreement to ensure they are fully informed of the remit of this pilot project.

Pharmacists and pharmacy technicians must restrict signposting of patients to the SRCXR service based on the criteria outlined within the patient eligibility section of this service level agreement.

The nominated responsible pharmacist assumes overall responsibility for ensuring that this pilot project is delivered within the remit of this service level agreement within the working hours of participating pharmacies.

5.3 Requirements for the West Yorkshire ICB Cancer Board pilot project team

Members of the pilot project team are responsible for provision of the training materials outlined in the training section of this service level agreement.

Members of the pilot project team are responsible for provision of project materials to participating community pharmacies (SRCXR signposting cards).

Members of the pilot project team are responsible for ongoing monitoring of the number of patients signposted from participating community pharmacies via the PharmOutcomes system (which will be funded by the pilot team). The pilot project team is responsible for identifying if/when the project nears the maximum number of patients who can be signposted within the available project budget (maximum number of patients 2500. Project team to inform participating pharmacies when the number of patients signposted reaches 2250 patients to reduce the potential for a project overspend).

Members of the pilot project team will be answerable to the West Yorkshire & Harrogate Cancer Alliance service innovation board for the implementation and outcomes of the pilot project as defined within the service innovation application.

5.4 Pharmacist/Pharmacy Technician Training

The pilot project team will be responsible for provision of training required for pharmacists and pharmacy technicians to support this project within participating community pharmacies.

This training will comprise of:

A recorded training video which will outline:

- The project background
- Patient eligibility criteria
- Patient symptoms which warrant signposting to the SRCXR service
- Details of the brief intervention
- Data collection requirements (using the PharmOutcomes software)

This recorded session will be made available online to all participating community pharmacies hosted on the Leeds Teaching Hospitals website and/or the Community Pharmacy West Yorkshire Site. This video will be no longer than 10 minutes in duration, and is anticipated to present minimal impact on operational capacity in participating community pharmacies.

A frequently asked questions document will also be made available to provide additional support to community pharmacists in practice.

6. Consent

As per the West Yorkshire & Harrogate Cancer Alliance pilot project application panel outcome, no patient consent is required for this pilot. Patients will be signposted to an existing SRCXR service which is in operation across Leeds and data collection is restricted to minimal non-patient identifiable data fields.

7. Patient Eligibility Confirmation, Brief Interventions & Signposting

7.1 Patient Eligibility Confirmation

Patients who are eligible to be signposted to the SRCXR service will be identified based on the patient criteria outlined in section 4 – patient eligibility.

Patients who fulfil the eligibility criteria should receive a brief intervention and be signposted towards the SRCXR service by a suitably trained pharmacist or pharmacy technician.

While patient eligibility should be based on symptom presentation, it is recognised that in practice many patients' prescriptions are prepared in advance of collection. It is acceptable for participating community pharmacies to highlight potentially eligible patients during preparation of prescribed medications which suggest that patients have worsening respiratory symptoms. However, all participating community pharmacies **must** ensure that patient eligibility is confirmed using the criteria outlined in the patient eligibility section upon collection of prescriptions, and then proceed with the brief intervention and signposting process if appropriate.

Please note, it is not acceptable for data for potentially eligible patients identified based on prescribed medications to be entered onto the PharmOutcomes system ahead of final confirmation of eligible upon collection of the prescription, conducting the brief intervention and then signposting.

It is also not acceptable to provide potentially eligible patients with SRCXR signposting cards without conducting the brief intervention and signposting processes.

Data submitted from participating pharmacies is monitored by the pilot project team for the duration of this pilot project.

7.2 Brief Intervention

Patients who are confirmed as eligible should receive a brief intervention as outlined in the training video created to support this project.

This brief intervention should provide patients with the following key messages:

- That they have symptoms which would benefit from a chest x-ray investigation
- That there is a self-referral chest x-ray service in operation within Leeds. This means they **do not** need to see their GP beforehand in order to attend.
- That this is a free service, and that they **do not** require an appointment to attend.

7.3 Signposting

- Patients should be provided with a SRCXR signposting card which has details of the service, venues and opening times
- Patients should be encouraged to bring this card with them when attending for a chest x-ray, however they should be assured that they will receive an investigation even if they forget to bring or misplace this card.
- The pharmacist conducting this brief intervention should note the unique identification number on the SRCXR signposting card provided to the patient. This will be entered onto the Pharm Outcomes data collection form.

Following completion of the patient eligibility confirmation, the brief intervention and signposting processes pharmacists should ensure that details of the consultation are recorded on the PharmOutcomes system as outlined in the records and data collection section.

8. Records and Data Collection

As per the West Yorkshire & Harrogate Cancer Alliance project application panel outcome decision, a limited, non-patients identifiable data set will be collected for all patients signposted to the SRCXR service from participating community pharmacies.

This data will be collected using the PharmOutcomes system, where a dedicated form to support this pilot project has been created.

This data will be limited to:

- Patient age (based on banded ages e.g. 40-45)
- Patients presenting symptom(s) which stimulated signposting to the SRCXR service (outlined below)
- The participating community pharmacy where the patient presented
- Details of any medications of interest which the patient was prescribed or sought to purchase over the counter at the time of presentation (outlined below).
- The unique number from the SRCXR signposting card provided to the patient from the participating community pharmacy

Symptom(s)

Please mark each of the symptom(s) the patient presents with. Please select all that apply:

Cough (> 3 weeks)	
Difficulty in breathing (> 3 weeks)	
Loss of weight or appetite (>3 weeks)	
Chest pain (>3 weeks)	
Fatigue or tiredness (> 3 weeks)	

Medication(s) – For patients any of the symptoms listed above please mark each of the medications that the patient is prescribed/sought to purchase OTC from the list below if applicable. If the patient was not prescribed any medications from this list or was not seeking to purchase any OTC treatments, please indicate as appropriate.

Prescribed medications	
Amoxicillin 500mg TDS for 5-7 days	
Amoxicillin 1000mg TDS for 5-7 days	
Clarithromycin 500mg BD for 5-7 days	
Doxycycline 200mg for 1 dose then 100mg OD for 4 days	

Doxycycline 200mg OD for 5 days	
Prednisolone 30mg OD 5-7 days	
No medications from the list above prescribed	

Over the counter medications	
Decongestants	
Cough suppressants	
Expectorants	
Advice only – no OTC medications purchased	

- Pharmacists or pharmacy technicians undertaking the brief intervention/signposting processes must record details of the consultation of the PharmOutcomes system using the dedicated data collection form created to support this pilot project.
- This process should be completed as soon as is practicable following the consultation and must be completed on the same working day as the consultation took place.
- The entry on the PharmOutcomes system will serve as a continuing record of the consultation

9. Governance

- This pilot project will adhere to the principle of data governance as outlined by NHS England.
- This pilot project will adhere to the principles of data governance stipulated by the West Yorkshire & Harrogate Cancer Alliance and the West Yorkshire ICB Cancer Board.
- It is not anticipated that participating community pharmacies will be required to record any data for patients signposted to the SRCXR outside of the remit of their normal operational models.
- All patient records will be managed in a manner which is consistent with the code of practice for health and social care services
- In the event of any incident related to provision of this service (outside of the scope of the routine incident reporting requirements), participating community pharmacies will be expected to notify the West Yorkshire ICB Cancer Board pilot project team.
- In line with Community Pharmacy Contractual Framework Safeguarding requirements where the pharmacist is concerned about a potential

safeguarding issue, then appropriate action should be taken, where necessary, in line with local safeguarding processes.

10. Payment

Funding for this pilot project has been provided by the West Yorkshire & Harrogate & Harrogate Cancer Alliance via the service innovation competition 2023/2024.

10.1 Service Payment

- Participating community pharmacies will be remunerated for each **completed** (patient eligibility confirmation, brief intervention and signposting) consultation which is recorded on the PharmOutcomes system as detailed within this service level agreement. This information will be used to generate the month end payment claim to participating pharmacies.
- Participating community pharmacies will be remunerated £10 for each patient who is signposted based on the criteria outlined within the service level agreement. The remuneration made to the pharmacy includes;
 - Set up costs (SOP development, staff training /awareness etc)
 - Pharmacist/Pharmacy technician time to undertake the required training
 - Pharmacist/Pharmacy technician time to provide the service intervention
 - Pharmacy staff time to support the pharmacist in providing the service (eg entering data onto PharmOutcomes)

10.2 Submission of Payment Claims

- Payments for participating community pharmacies will be based on activity recorded using the PharmOutcomes system. Provision of payment will be managed by Community Pharmacy West Yorkshire on behalf of the West Yorkshire ICB Cancer Board.
- Pharmacy Contractors must record the information onto PharmOutcomes within 48 hours of the brief intervention and signposting. Consultations recorded outside of this timeframe may not be considered eligible for remuneration. Claims submitted which relate to interventions over one month old will not be considered eligible for remuneration.

11. Equipment

To facilitate participation in this pilot project, community pharmacies will be provided with the following materials:

- Access to the recorded training materials (online)

- Access to the frequently asked questions sheet (online)
- Printed copies of SRCXR signposting card (with unique number)

Participating community pharmacies will be provided with sufficient stock of printed SRCXR signposting cards to meet anticipated demand at the point of initiation. In the event that pharmacies require any additional cards, they can contact the West Yorkshire ICB Cancer Board project team via Community Pharmacy West Yorkshire to arrange for further supply.

12. Time Period of this Service Level Agreement

This pilot project aims to run for a 6 month period between 1/2/24 and 31/7/24. This service level agreement will cover activity undertaken to support this project within this stated time period.

SCHEDULE 2 – THE SERVICES

Ai. Service Specifications – Enhanced Health in Care Homes

Not Applicable.

SCHEDULE 2 – THE SERVICES

B. Indicative Activity Plan

Not Applicable

D. Essential Services (NHS Trusts only)

Not Applicable

G. Other Local Agreements, Policies and Procedures

Not applicable

J. Transfer of and Discharge from Care Protocols

Not applicable

K. Safeguarding Policies and Mental Capacity Act Policies

Safeguarding and the Protection of Children and Adults at Risk including the Mental Capacity Act (MCA) Standards

The Provider will have its own Safeguarding and Mental Capacity Act policies and procedures that adhere to the agreed Multi-agency Policies and procedures for Safeguarding Adults and for Safeguarding Children and relevant current legislation.

The Provider will comply with the West Yorkshire Integrated Care Board (ICB) Safeguarding Standards relevant to each organisation. The Safeguarding Standards are embedded below, and the provider is expected to comply with any requests for the completion and submission of these to provide safeguarding assurance.



8. WY&H
Safeguarding standar

Self-assessment tools:



PROVIDER



PROVIDER

SAFEGUARDING STAISTANDARDS FOR THI

Provider Polices.

The pharmacy will have available up to date Safeguarding and Mental Capacity Act policies for commissioner review on request.

SCHEDULE 3 – PAYMENT

B. Locally Agreed Adjustments to NHS Payment Scheme Unit Prices

For each Locally Agreed Adjustment to NHS Payment Scheme Unit Prices which has been agreed for this Contract, copy or attach the completed publication template required by NHS England, or state Not Applicable. Additional locally agreed detail may be included as necessary by attaching further documents or spreadsheets.

Templates for locally-agreed adjustments are available at <https://www.england.nhs.uk/pay-syst/nhs-payment-scheme/>

Not Applicable

C. Local Prices

- Participating community pharmacies will be remunerated for each completed (patient eligibility confirmation, brief intervention and signposting) consultation which is recorded on the PharmOutcomes system as detailed within this service level agreement.
- Participating community pharmacies will be remunerated £10 for each patient who is signposted based on the criteria outlined within the service level agreement.

D. Expected Annual Contract Values

Not Applicable

SCHEDULE 4 – LOCAL QUALITY REQUIREMENTS
SCHEDULE 5 - GOVERNANCE

B. Provider’s Material Sub-Contracts

Sub-Contractor [Name] [Registered Office] [Company number]	Service Description	Start date/expiry date	Processing Personal Data – Yes/No	If the Sub-Contractor is processing Personal Data, state whether the Sub- Contractor is a Data Processor OR a Data Controller OR a joint Data Controller
Insert text locally or state Not Applicable				

SCHEDULE 6 – CONTRACT MANAGEMENT, REPORTING AND INFORMATION REQUIREMENTS

A. Reporting Requirements

	Reporting Period	Format of Report	Timing and Method for delivery of Report
Local Requirements Reported Locally			
<p>Data Collection and Recording (via PharmOutcomes)</p> <p>As outlined in the separate service level agreement between the West Yorkshire ICB Cancer Board and community pharmacy providers, a limited, non-identifiable data set will be collected as part of this pilot project. This data will be collected in participating community pharmacies using the PharmOutcomes system.</p> <p>To facilitate this data collection, a dedicated form will be created on the PharmOutcomes system by the Community Pharmacy West Yorkshire team under the supervision of and using data fields supplied by the West Yorkshire ICB Cancer Board pilot project team.</p> <p>This data collection form will include the following:</p> <ul style="list-style-type: none"> • Details of the participating community pharmacy site which submitted the data following completion of the patient signposting process (as outlined in the separate service level agreement) • The date upon which this data was submitted by the participating community pharmacy site • A data field for pharmacists completing the data collection form to include the unique number on the SRCXR signposting card provided to the patient signposted to the SRCXR service • Confirmation of patient eligibility submitted by the participating community pharmacy site: 			

	Reporting Period	Format of Report	Timing and Method for delivery of Report
<ul style="list-style-type: none"> ○ Patients must be at least 40 years old at the time when they are signposted ○ Patients must not have received a chest x-ray in the 3 months (12 weeks) before being signposted ● Details of patients symptom(s) from the following list: <ul style="list-style-type: none"> ○ Cough > 3 weeks ○ Difficulty in breathing > 3 weeks ○ Loss of weight or appetite > 3 weeks ○ Chest pain > 3 weeks ○ Fatigue or tiredness > 3 weeks ● Details of any medications that the patient was prescribed, sought to purchase at the time that they were signposted from the following list: <ul style="list-style-type: none"> ○ Prescribed medications ○ Amoxicillin 500mg TDS for 5-7 days ○ Amoxicillin 1000mg TDS for 5 -7 days ○ Clarithromycin 500mg bd for 5-7 days ○ Doxycycline 200mg for 1 dose then 100mg OD for 4 days ○ Doxycycline 200mg OD for 5 days ○ Prednisolone 30mg OD for 5-7 days ○ No medications from this list prescribed at the time of signposting ○ Over the counter medications ○ Decongestants ○ Cough suppressants ○ Expectorants ○ Advice only – no OTC medications purchased 			

SCHEDULE 6 – CONTRACT MANAGEMENT, REPORTING AND INFORMATION REQUIREMENTS

E. Provider Data Processing Agreement

NOT APPLICABLE

SCHEDULE 7 – PENSIONS

<p>Not Applicable</p>

SCHEDULE 8 – TUPE*

NA to this service

NHS England
Wellington House
133-155 Waterloo Road
London
SE1 8UG

Contact: england.contractshelp@nhs.net

This publication can be made available in a number of alternative formats on request

© NHS England March 2023 | PRN00258